Polaris Group (6550) Fair Value & Analysis
Healthcare · TW · Market cap 10.8B TWD
Fair value as of: Aug 19, 2026
From 1 valuation models · updated today
Fair value updated Aug 19, 2026, revised from 0.1600 TWD to 5.10 TWD (+3,087.5%) since Aug 13, 2026. Share price −17.5% over the past month.
Below-average quality, and screening another 50% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (6.38 TWD). The favourable scenario is already priced in.
- Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (3.51 TWD to 6.38 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
60‑month range 10.15 TWD – 218.00 TWD · fair‑value band 3.51 TWD – 6.38 TWD · the 10.15 TWD price screens above the 5.10 TWD fair value. Dashed = 300-day average. As of Aug 19, 2026.
Analysis
Polaris Group (6550) currently trades at 10.15 TWD, while our model-based Fair Value estimate is 5.10 TWD, implying the stock looks roughly 49.8% overvalued today. The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 69.3M TWD. It earns a return on equity of -69.5%. Net debt stands at 517M TWD. Fundamentals as of Aug 19, 2026
Our scenario range runs from 3.51 TWD (bear case) to 6.38 TWD (bull case); at 10.15 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 77% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -63% fair-value upside, at -50%, 6550 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 6550 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 30 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Polaris Group, together with its subsidiaries, offers biotechnology, pharmaceutical testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It also offers healthcare consulting, staffing, and MDS solutions.
Full company description
Polaris Group, together with its subsidiaries, offers biotechnology, pharmaceutical testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It also offers healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Cayman Islands.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Polaris Group reported revenue of 40.6M TWD in FY2025 versus 15.0M TWD in FY2021, a compound +28.2%/yr. Reported net income was −3.9B TWD in FY2025.
6550 screens 50% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 616 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| WuXi Biologics (Cayman) Inc 2269 | HK$45.70 | HK$30.58 | -33% |
| Innovent Biologics, Inc 1801 | HK$95.55 | HK$19.68 | -79% |
| Genmab A/S GMAB | kr 2,104 | kr 250.07 | -88% |
| Sino Biopharmaceutical Limited 1177 | HK$4.87 | HK$3.37 | -31% |
| RemeGen Co 688331 | ¥131.87 | ¥23.19 | -82% |
| ALTEOGEN Inc 196170 | 314,000 KRW | 39,476 KRW | -87% |
| Biocon Limited BIOCON | ₹417.50 | ₹52.10 | -88% |
Compare Polaris Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Polaris Group (6550) overvalued or undervalued?
What is the fair value of 6550?
What is the quality score of 6550?
What is the revenue of Polaris Group (6550)?
What is the net profit margin of 6550?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Polaris Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.